Polycystic liver
Explore liver cysts in PKD1/PKD2 carriers and isolated polycystic liver disease. A review, a nationwide survey and a single case offer different kinds of evidence; none replaces an individual assessment.
Cards in this collection
-
Scoping Review on Polycystic Liver Disease in PKD1/PKD2 Gene Carriers: Genetic Aspects, Pathophysiology, and Therapeutic Approaches
A review of 29 studies on polycystic liver disease in people with PKD1 or PKD2 variants explains why liver cysts can grow with kidney cysts, how genetics may relate to severity, and which treatments help selected patients with bothersome liver size. Somatostatin-type medicines remain the main drug approach discussed; other options such as mTOR inhibitors look mixed.
-
Limitations of MELD in Isolated Polycystic Liver Disease: Fatal Traumatic Cyst Rupture Complicated by Abdominal Compartment Syndrome.
A man whose liver was crowded with cysts but whose blood tests looked fine scored too low for a liver transplant. After wasting away he was listed — then a bump burst a cyst and he died. MELD scores can miss real suffering in polycystic liver disease; repeat checks matter.
-
Healthcare burden and clinical spectrum of symptomatic polycystic liver disease in Japan: a nationwide epidemiological survey
Many people with polycystic liver disease have no symptoms, but some develop a swollen belly, pain or infected liver cysts. A nationwide survey of hospital departments in Japan estimated that about 3,570 people were being treated or followed for symptomatic polycystic liver disease in 2023, around 29 per million people. Among 557 patients with detailed data, most were women and about two thirds also had polycystic kidney disease. More than half had treatment for their liver cysts, and many needed care from more than one department or hospital. The study describes the condition in one country; it does not test treatments.